Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChimeriVax-JE dose-ranging study
NCT00981630Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2004
- Primary completion
- Feb 2006
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of japanese encephalitis chimeric virus vaccine in Japanese encephalitis (JE) (4 arms), sponsored by Sanofi. Primary endpoints: Number of Participants Who Seroconverted to the Respective Homologous JE Vaccine Strain at Day 30, Number of Participants Who Seroconverted to Wild Type JE Virus Strains at Day 30 and 1 more. Started Nov 2004; status: completed.
02
Drugs
japanese encephalitis chimeric virus vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on NCT00981630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00981630.